Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/8780
Title: | Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer | Authors: | Tepeli, Emre Caner, Vildan Büyükpınarbaşılı, N. Çetin, Gökhan Ozan Düzcan, Füsun Elmas, Levent Bağcı, Gülseren |
Keywords: | ERCC1 IHC Non-small cell lung cancer Real-time quantitative PCR DNA excision repair cross complementing protein 1 messenger RNA aged article cancer staging clinical feature controlled study DNA repair down regulation excision repair cross complementing group 1 gene female gene expression regulation gene function gene identification genetic association genetic marker histopathology human human tissue immunohistochemistry lung non small cell cancer major clinical study male molecular pathology oncogene protein expression real time polymerase chain reaction upregulation validation process |
Publisher: | Kluwer Academic Publishers | Abstract: | Excision Repair Cross-Complementing Group 1 (ERCC1) is an important DNA repair gene, playing critical role in nucleotide excision repair pathway and having a significant influence on genomic instability. Some studies support that ERCC1 might be a potential predictive and prognostic marker in non-small cell lung cancer (NSCLC). ERCC1 has also been shown to be a promising biomarker in NSCLC treated with a cisplatin-based regimen. Therefore, the determination of ERCC1 expression at DNA, mRNA and protein level in different stages of NSCLC is still an important topic in the cancer. Ninety-one formalin-fixed paraffin-embedded tumor samples histopathologically diagnosed as NSCLC were examined in this study. ERCC1 expression at protein level were scored by immunohistochemistry. The gene amplification and mRNA expression levels for ERCC1 were determined by real-time quantitative PCR. There was complete concordance among the three methods in 39 tumor samples (42.9%). A strong correlation was found between DNA amplification and mRNA expression (r = 0.662) while there was no correlation between mRNA and protein assessment for ERCC1 expression (r = -0.013). ERCC1 expression at mRNA and DNA level (63.1 and 84.2%, respectively) in tumors at stage III was higher than at the other stages. In contrast, the protein expression at stage II and III (56.6 and 52.6%, respectively) of NSCLC was lower than that of tumors with stage I NSCLC. These results show that the mechanism by which ERCC1 expression might play a role in tumor behavior. This study was also confirmed that the appropriate validation and qualification in methods used for ERCC1 status were needed before its clinical application and implementation. © 2011 Springer Science+Business Media B.V. | URI: | https://hdl.handle.net/11499/8780 https://doi.org/10.1007/s11033-011-0743-0 |
ISSN: | 0301-4851 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
10
checked on Nov 30, 2024
WEB OF SCIENCETM
Citations
7
checked on Dec 1, 2024
Page view(s)
56
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.